Neuphoria Therapeutics Inc. (NEUP)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 51/100 (HIGH), 13.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.48% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
- Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell
- Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
- Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial
- Scancell confirms advanced talks over reverse merger with Neuphoria
- Scancell sees high demand in retail share offer, seals £15.7m from UK investors
- SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612
- Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Neuphoria Therapeutics Inc..
Full NEUP Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.